Program
olpasiran
Also written as “Olpasiran” and “AMG 890”.
Its studies are mostly in Cardiovascular Diseases · Atherosclerosis · Renal Insufficiency, led by Amgen.
Furthest: phase 3, since Oct 12, 20229 company-led studies, 3 open or runningNext primary completion: Mar 31, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 93 open or running | phase 3since Oct 12, 2022 | Jun 19, 2018 | Mar 31, 2028phase 3 · NCT05581303 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 19, 2018First study: phase 1 study in Cardiovascular DiseasesFirst studyNCT03626662 · 79 enrolled · United States, Australia
- Feb 13, 2020Phase 2 study in Cardiovascular DiseasesNCT04270760 · 281 enrolled · United States, Australia, Canada and more
- Jul 26, 2021Phase 1 study in Elevated Serum Lipoprotein(a)NCT04987320 · 24 enrolled · Hong Kong
- Jul 28, 2022Phase 1 study in Hepatic ImpairmentNCT05481411 · 25 enrolled · United States
- Aug 3, 2022Phase 1 study in Renal InsufficiencyNCT05489614 · 33 enrolled · United States
- Oct 12, 2022Phase 3 study in AtherosclerosisNCT05581303 · 7,297 enrolled · United States, Australia, Austria and more
- Apr 29, 2024Phase 1 study in Basic ScienceNCT06411860 · 32 enrolled · United Kingdom
- Aug 18, 2025Phase 3 study in Cardiovascular DiseasesNCT07136012 · 11,000 planned · United States, Australia, Canada and more
- Dec 17, 2025Phase 3 study in Cardiovascular DiseasesNCT07293260 · 406 planned · United States, Australia, Canada and more
Ahead
- Mar 31, 2028Primary completion: phase 3 study in AtherosclerosisNCT05581303
- Jun 15, 2028Primary completion: phase 3 study in Cardiovascular DiseasesNCT07293260
- Oct 20, 2031Primary completion: phase 3 study in Cardiovascular DiseasesNCT07136012
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07293260Cardiovascular Diseases · United States, Australia, Canada and more | 3 | Recruiting | Jun 15, 2028 | 406 |
| NCT07136012Cardiovascular Diseases · United States, Australia, Canada and more | 3 | Recruiting | Oct 20, 2031 | 11,000 |
| NCT06411860Basic Science · United Kingdom | 1 | Completed | Nov 29, 2024 | 32 |
| NCT05581303Atherosclerosis · United States, Australia, Austria and more | 3 | Active, not recruiting | Mar 31, 2028 | 7,297 |
| NCT05489614Renal Insufficiency · United States | 1 | Completed | Oct 24, 2023 | 33 |
| NCT05481411Hepatic Impairment · United States | 1 | Completed | Apr 5, 2023 | 25 |
| NCT04987320Elevated Serum Lipoprotein(a) · Hong Kong | 1 | Completed | Nov 12, 2021 | 24 |
| NCT04270760Cardiovascular Diseases · United States, Australia, Canada and more | 2 | Completed | Dec 27, 2021 | 281 |
| NCT03626662Cardiovascular Diseases · United States, Australia | 1 | Completed | Apr 18, 2023 | 79 |
How it is read
Names in the registry
- “Olpasiran”, 8 entries
- “AMG 890”, 1 entry
Conditions, from the studies’ own filings
- Cardiovascular Diseases, 4 studies
- Atherosclerosis, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.